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Abstract
Background: Presenilin-1 (PSEN1) is one of the causative genes for early onset Alzheimer’s disease (EOAD).
Recently, emerging studies reported several novel PSEN1 mutations among Asian. We describe a male with EOAD
had a pathogenic PSEN1 mutation.
Case presentation: A 53-year-old male presented with memory decline, followed by difficulty in finding ways. Patient had
positive family history, since his mother and one of his brother was also affected with dementia. Brain magnetic resonance
imaging (MRI) scan showed mild degree of atrophy of bilateral hippocampus and parietal lobe. 18F-Florbetaben-PET (FBB-
PET) revealed increased amyloid deposition in bilateral frontal, parietal, temporal lobe and precuneus. Whole exome analysis
revealed a heterozygous, probably pathogenic PSEN1 (c.695G> T, p.W165C) mutation. Interestingly, Trp165Cys mutation is
located in trans membrane (TM)-III region, which is conserved between PSEN1/PSEN2. In vitro studies revealed that PSEN1
Trp165Cys could result in disturbances in amyloid metabolism. This prediction was confirmed by structure predictions and
previous in vitro studies that the p.Trp165Cys could result in decreased Aβ42/Aβ40 ratios.
Conclusion:We report a case of EOAD having a pathogenic PSEN1 (Trp165Cys) confirmed with in silico and in vitro
predictions.
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Background
Alzheimer’s disease (AD) (MIM #104300) is a neurodegen-
erative disease among elderlies, which is resulted by abnor-
mal protein assembly inside the brain. Extracellular and
intracellular amyloid beta (Aβ) and Tau protein, respect-
ively, were associated as the main hallmarks of the disease.
Early onset AD (EOAD) and late onset AD (LOAD) are the
two main forms of the disease. Three genes were verified as
causative factor for EOAD: amyloid precursor protein
(APP) (MIM #104760) [1], presenilin 1 (PSEN1) (MIM
#104311) [2], and presenilin 2 (PSEN2) (MIM #600759) [3].
Approximately 300 mutations of PSEN1, PSEN2, and APP
in 635 affected individuals or families have been reported in
the Dementia Mutation Database [4] (https://www.alzforum.
org/mutations). Majority of mutations were observed in
PSEN1 [5–7] (n= 219, 76.6%) with over 230 mutations re-
ported as pathogenic in the Alzforum database (https://
www.alzforum.org/mutations/psen-1), as compared to
APP (n = 51, 17.8%), and PSEN2 (n = 16, 5.6%) [8–11].
PSEN1 protein contains nine transmembrane (TM) do-
mains, connected with hydrophilic loop regions. As the
member of γ- secretase complex, PSEN1 could function as a
catalytic subunit of aspartyl protease, involved in the cleavage
of C99 residue in APP protein into β-amyloid (Aβ) peptide.
PSEN1 mutations may impair the γ-secretase processing,
resulting in altered of Aβ production. Gain-of-function mu-
tations could increase the amyoid processing and the ratio
Aβ42/Aβ40 [12, 13]. Loss- of- function mutations may re-
duce protective mechanisms, such as α-secretase cleavage
[14]. In addition, accumulation of amyloid peptides may also
associated with the reduced Aβ42 clearance [15] and neur-
onal loss [15–17]. In majority of patients, disease occurred at
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40–50 years of age [18–21]. Several cases of young
onset AD have been reported, where patients were
less than 30–40 years of age [6, 7, 22–31]. Guerrio et
al. (2010) designed an algorithm for variants in
EOAD causative genes [32] on prediction of the
pathogenic nature of novel mutations. Investigating
patients carrying novel as well as previously known
mutations along with the associated phenotypes will
aid in classification of these variants and may eventu-
ally support genetic counseling [33]. In this study, we
reported a pathogenic PSEN1 W165C mutation as de-
termined by genetic testing in a Korean patient with
EOAD.
Case presentation
A 53-year-old man with 13 years of education presented
with progressive memory decline. At aged 50, he com-
plained forgetfulness of meetings or details of story, and re-
peating the same questions. He had difficulty in orienting
to date and in finding way to a new place. His past medical
history revealed myocardial infarction with proper medical
treatment. His Korean version of Mini-Mental Status
Examination (K-MMSE) score was 21/30 and clinical de-
mentia rating scale (CDR) score was 0.5 at three years after
symptom onset. And follow-up K-MMSE score at six years
after symptom onset was 19/30 and CDR score was 1. His
brain MRI at three years after symptom onset revealed mild
atrophy of bilateral hippocampus and parietal lobe (Fig. 1a).
FBB-PET at five years after symptom onset showed in-
creased amyloid deposition in bilateral parietal, frontal,
temporal lobe and precuneus (Fig. 1b). The patient had an
APOE ε2 /ε3 polymorphism.
A 53-year-old man (III-1, Fig. 2) visited the Seoul
National University Bundang Hospital with gradually
impaired cognitive function over the previous years. The
proband’s family history had a strong family history of de-
mentia, and presented several family members affected by
EOAD (Fig. 2). His mother (II-2) suffered from AD
with onset in her fifties and deceased. The patient
was one of the 4 siblings, comprising 2 brothers and
2 sisters. His first younger brother (III-2) was also di-
agnosed AD deceased in his forties, and had 2 chil-
dren. His second younger brother (III-5) and his two
younger sisters (III-3, III-4) displayed normal cogni-
tive function. The health condition of the rest of his
family members remained unknown, since all living
family members and relatives declined to provide any
additional information regarding their health.
Genetic analysis of PSEN1 and structural
prediction of mutant PSEN 1 protein
Methods
An in depth genetic screen was performed using a specif-
ically expanded panel of 50 causative and risk factor genes
for various neurodegenerative disorders [34]. Whole ex-
ome sequencing (WES) was performed in Novogene.
Standard Sanger sequencing was carried out by BioNeer
Inc. (Dajeon, Republic of Korea) [34]. Big Dye Terminator
Cyclic sequencing was performed using the ABI 3730XL
DNA Analyzer (Bioneer Inc., Dajeon, Republic of Korea).
Sequencing data was analyzed using NCBI Blast (http://
blast.ncbi.nlm.nih.gov/Blast.cgi) and the chromatograms
were screened using the DNA BASER (http://www.dnaba-
ser.com) tool. Possible novel mutations were checked in
the Korean Reference Genome Database (KRGDB; http://
nih.go.kr/menu.es?mid=a50303020300), which was ob-
tained by whole genome sequencing of 622 healthy
Fig. 1 Brain functional and structural neuroimaging data of the proband at diagnosis. a. Axial FLAIR, coronal, and sagittal T1 images of brain MRI,
arrows pointing at left-dominant bilateral temporal lobe atrophy. b. FDG-PET, arrows pointing at hypometabolism in left temporal cortex, right
anterior temporal cortex and bilateral frontal cortex
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Korean individuals. The mutations were also screened
against Broad Institute’s Genome Association Database
(genome AD, http://gnomad.broadinstitute.org) and 1000
Genomes (http://www.1000genomes.org/) databases.
The possible pathogenic nature of missense variants was
predicted using simple online tools, such as PolyPhen-2
(http://genetics.bwh.harvard.edu/pph2), Sorting Intolerant
from Tolerant (SIFT; http://sift.jcvi.org/), and PROVEAN
(http://provean.jcvi.org) algorithms. ExPasy analysis was
also performed (https://www.expasy.org/) using different
parameters, such as Kyte and Doolittle hydrophobicity
index, bulkiness, and polarity. Mutant and normal prion
protein structures were compared by 3D modelling. Pro-
tein structures were built using the Raptor X web server
(http://raptorx.uchicago.edu/), while Discovery Studio 3.5
Visualizer (Accelrys, San Diego, USA) was used to display
the 3D images [35].
Results
A heterozygous G > T substitution (chr14; g.73653575:
G > T) was discovered and confirmed to occur in the
PSEN1 coding region using both WES and standard
sequencing. This mutation caused the change from
tryptophan to cysteine (c.495G > C; p.Trp165Cys) sub-
stitution, located at exon 6 of PSEN1 gene, and in
transmembrane (TM) helix domain-III of the PSEN1
protein (Fig. 3).
The mutation is associated with EOAD patient with
memory decline, followed by difficulty in finding ways
and had a strong family history of AD; however, the
specific mechanism is not functionally uncovered. The
mutation was found in subject a Korean patient with
EOAD and not observed in KRGDB, ExAC, and 1000gen-
ome control data sets. All in silico pathogenicity programs
predicted the mutation to be deleterious. Figure 4
predicted that abnormal conformation inside the helix re-
sults in the mutated form due to an abnormal intra-or
intermolecular disulfide bridge associated with the poten-
tial re-activities with metals or other compounds with
thiol groups. Additionally, cysteine is not common re-
corded in the helix, further suggesting that this mutation
might lead to abnormal conformation within the TM re-
gion. The intramolecular interactions may also change
with the mutation: Trp165 has strong interaction with
Ser169 (two hydrogen bonds), and forms another hydro-
gen bond with Val161. Cys165 changes the hydrogen
bonds significantly. The interaction with Ser169 and Val
169 remained, but with Ser169, only one hydrogen bond
was visible. Two new interactions could be seen with
Ile162 and Ile168 (Fig. 5) In addition, the mutation is lo-
calized to trans membrane-III region conserved between
PSEN1/PSEN2 and expected to affect Ab42 levels. This
hypothesis was previously demonstrated that PSEN1
W165C led to increase Aβ42 and decreased Aβ40, result-
ing in elevated Aβ42/Aβ40 ratio in gaining loss of function
in presenilin [36–39].
Discussions
Since four different populations have been previously
described the PSEN1 Trp165 from four familial AD
cases (Table 1), the 165 codon seems to be a very
vulnerable site. Initially, PSEN1 Trp165Cys mutation
was found in a French family, with a codon combin-
ation of TGG > TGC. Mutation was associated with
strongly was positive family history, since several af-
fected family members were identified in three gener-
ations. Age of onset ranged between 37 and 47 years
in the relatives with disease. No details were available
Fig. 2 Family tree of patient with PSEN1 W165C mutation. White squares and circles mean asymptomatic family members, which were not
diagnosed with disease. Family members which were crossed out, already died. Arrows show the proband patient
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on clinical symptoms of affected patients [36]. Second
case of Trp165Cys was discovered with alternative
codon exchange of TGG > TGT in an Indian family.
Affected patients developed disease in their 40s, and
disease phenotypes were rapid progressive disease
progression and cerebral/cerebellar atrophies [37].
Our case was associated with probable EOAD case in
a male patient, and his family members presented AD
in their 40s. It may be difficult to find out, whether
there could be a common founder between the Indian
and Korean families. Since the Korea and India may
be geographically isolated from each other, we suggest
Fig. 3 WES data of PSEN1 W165C mutation, verified by standard sequencing
Fig. 4 In silico structure predictions on PSEN1 W165C mutation. 3D modeling on PSEN1 Trp165Cys mutation, compared to the normal PSEN1.
Alanine is labeled with blue while valine is labeled with yellow
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that PSEN1 Trp165Cys occur independently in these
two families.
PSEN1 Trp165Cys is located in the TM-III region of
PSEN1 protein. An exchange from native amino acid to
Cys may increase the risk of an abnormal intramolecular
disulfide bond formation with another Cys. These new S-S
bonds may create novel inter- or intramolecular structures,
involving in pathogenic mechanisms. The potential mech-
anism was displayed and revealed the Fig. 5. In addition, at
the residue, another mutation to glycine (Gly, G) was previ-
ously documented in a Japanese family with young onset
AD [39], suggesting that this residue may be critical for
PSEN1 function. Interestingly, the mutation is located to
TM-III region conserved between PSEN1/PSEN2 and ex-
pected to affect Ab42 levels. This prediction was previously
demonstrated that PSEN1 Trp165Cys resulted in increased
Aβ42 and decreased Aβ40, respectively. It could lead to ele-
vated Aβ42/Aβ40 ratio in gaining loss of function in
Fig. 5 Putative intramolecular interactions in PSEN1 with Trp165 and PSEN1 with Cys165
Table 1 Clinical findings in the published at codon 165 of PSEN1
Campion et al., 1999 [36]
Wallon et al., 2012 [38]
Higuchi et al.,
2000 [39]
Syama et al., 2018 [37] This study
Country France Japan India Korea
Mutation Trp165Cys Trp165Gly Trp165Cys Trp165Cys





Age at onset (year) 37–47 34–38 45 50
ApoE genotype ε3/ε3 NA NA ε2/ε3
Clinical signs and
symptoms
EOAD EOAD NA Memory decline, followed
by difficulty in finding ways




NA NA MRI: indicated diffuse cerebral
and cerebellar atrophy in one case.
18F-Florbetaben-PET (FBB-PET):
increased amyloid deposition in
bilateral frontal, parietal, temporal
lobe and precuneus




↑Aβ42 and ↓Aβ40 production in vitro;
elevated Aβ42/Aβ40 ratio
↑Aβ42 and ↓Aβ40 production in
vitro; elevated Aβ42/Aβ40 ratio.
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presenilin [36–39], verifying as a pathogenic mutation, in-
volved in EOAD. This mutation was associated with rapid
progression of disease, since the duration from the first
clinical symptoms to the death ranged 4–10 years. Earlier
onset of disease (37–47 years) was observed in a French
family, but there was no information on the clinical symp-
toms in this family (Table 1).
Several pathogenic PSEN genes are found to cluster
within the predicted α-helical TMs. Among other
TMs, TM3 has been identified as one of the critical
site in PSEN1, where several familiar AD (FAD)
mutations were found. Recently, more than twenty
mutations associated with FAD have been reported in
TM-III of PSEN1 [36, 40–50] (Fig. 6), and several of
them were associated with EOAD (Table 2). Among
these mutations, the PSEN1 Trp165Cys mutation is of
particular interest because it may be associated with
disease early onset. Moreover, the Trp165Cys muta-
tion could cause increase in the Aβ42/Aβ total ratio
[36–39], similarly to other FAD-associated PSEN1
H163R [51], H163Y [52], L166P [53], I167del [54],
S170F [31] S170P [40], L174del [44], L173W [36] and
L174M [45] mutations.
In our case, the PSEN1 p.Trp165Cys variant has been
identified in a patient with early onset of age (50s years
at diagnosis), suggesting that disease phenotype may be
the result of amino acid substitution in this conservative
residue. Furthermore, the amino acid position 165, lo-
cated in the TM-III of PSEN1 indicated a significant
phylogenetic conservation among vertebrates, and in
homologous proteins such as PSEN2, suggesting that the
position is of functional significance. Importantly, the
patient’s mother and his brother were also affected by
AD that is likely to involve autosomal dominant AD.
Guerrio et al. (2010) designed an algorithm on muta-
tions on PSENs. which may be helpful in prediction on
their pathogenic nature [32]. PSEN1 Trp165Cys may be a
definitely pathogenic mutation. The Korean case of
PSEN1 Trp165Cys may be associated with positive family
history of disease, since the mother and one of the brother
of patient was affected with AD. This is the third case of
Trp165Cys, described all around the world, and EOAD
was observed in all cases of AD. All of these findings sug-
gested that Trp165 may be an important in PSEN1, since
it bound two pathogenic mutations, Trp165Cys and
Trp165Gly [36–38]. Functional studies, performed by Sun
et al. (2016) revealed that mutation may impair the
gamma secretase activity, resulting in elevated amyloid
beta 42 production [55]. Our findings confirmed the sig-
nificance of PSEN1 Trp165Cys in EOAD.
Fig. 6 Mutations, discovered and located in the TM-III of PSEN1 protein
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Conclusions
We confirm that PSEN1 p.Trp165Cys may be commonly
associated with EOAD. Our findings were consistent
with the previously reported cases of this mutation, and
supported the hypothesis that PSs contribute the identi-
fication of at risk relatives who may be potential candi-
dates for clinical trials.
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